14-day Premium Trial Subscription Sign Up For FreeGet Free

Alexion Pharmaceuticals Stock Forecast NASDAQ:ALXN

Price Target and Analyst Ratings

Most Recent Rating

Oppenheimer is very positive about ALXN and gave it a "Market Perform - Outperform" rating on May 05, 2021. The price target was set to $205.00.

Last 30 Days

Historical Ratings

Date Rating Action Authority Current Price Target Price
2021-05-05 Market Perform - Outperform Upgraded by Oppenheimer $169.91 $205.00
2021-05-03 Market Perform Target Raised by SVB Leerink $170.27 $156.00 → $173.00
2021-04-26 Neutral Initiated by Credit Suisse Group $167.00 $190.00
2021-03-29 Outperform - Market Perform Reiterated by SVB Leerink $155.57 $196.00 → $156.00
2021-03-23 Outperform - Market Perform Downgraded by SVB Leerink $152.18 $196.00 → $156.00
2021-02-05 Outperform Target Lowered by SVB Leerink $153.92 $200.00 → $196.00
2021-02-04 Overweight - Neutral Downgraded by Piper Sandler $155.59
2021-01-08 Outperform - Market Perform Downgraded by Raymond James $157.35
2020-12-16 Buy - Hold Downgraded by Truist $158.03 $155.00 → $175.00
2020-12-16 Buy - Hold Downgraded by Truist $158.03 $175.00
2020-12-15 Buy - Neutral Reiterated by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $157.91 $175.00
2020-12-15 Buy - Neutral Downgraded by Smith Barney Citigroup $157.91 $175.00
2020-12-15 Target Raised by Roth Capital $157.91 $50.00 → $73.00
2020-12-14 Outperform Target Raised by SVB Leerink $156.31 $159.00 → $200.00
2020-12-14 Outperform - Neutral Downgraded by Robert W. Baird $156.31 $140.00 → $175.00
2020-12-14 Outperform - Neutral Downgraded by Wedbush $156.31 $175.00
2020-12-14 Outperform Target Raised by Royal Bank of Canada $156.31 $139.00 → $175.00
2020-12-14 Outperform - Neutral Downgraded by Robert W. Baird $156.31 $175.00
2020-12-14 Outperform - Market Perform Downgraded by BMO Capital Markets $156.31 $152.00 → $175.00
2020-12-14 Outperform - Neutral Downgraded by Credit Suisse Group $156.31 $147.00 → $194.00
2020-11-19 Market Perform Initiated by Sanford C. Bernstein $122.05
2020-11-05 Buy Reiterated by Royal Bank of Canada $125.44
2020-11-05 Target Raised by Smith Barney Citigroup $125.44 $145.00 → $157.00
2020-11-05 Target Raised by Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell $125.44 $145.00 → $157.00
2020-10-30 Outperform Target Raised by SVB Leerink $115.14 $159.00 → $163.00
2020-10-30 Equal Weight Target Lowered by Morgan Stanley $115.14 $121.00 → $119.00
2020-10-29 Overweight Target Raised by Piper Sandler $118.21 $175.00 → $179.00
2020-10-28 Neutral Initiated by UBS Group $114.85 $133.00
2020-10-13 Equal Weight Target Raised by Morgan Stanley $123.75 $120.00 → $121.00
2020-10-07 Hold Reiterated by William Blair $125.33
2020-10-07 Outperform Target Raised by Royal Bank of Canada $125.33 $136.00 → $139.00
2020-10-06 Outperform Reiterated by Wedbush $116.08
2020-09-01 Hold Target Lowered by Stifel Nicolaus $112.68 $120.00 → $117.00
2020-07-31 Outperform Target Raised by SVB Leerink $102.49 $159.00 → $163.00
2020-07-31 Outperform Target Lowered by Raymond James $102.49 $156.00 → $151.00
2020-07-30 Outperform - Market Perform Downgraded by William Blair $104.81
2020-07-30 Hold Reiterated by Oppenheimer $104.81
2020-06-01 Outperform Target Raised by Credit Suisse Group $118.92 $142.00 → $147.00
2020-06-01 Outperform Target Raised by Wedbush $118.92 $120.00 → $138.00
2020-05-29 Outperform Target Raised by SVB Leerink $119.90 $150.00 → $159.00
2020-05-08 Buy Target Lowered by SunTrust Banks $97.34 $141.00 → $135.00
2020-05-07 Outperform Target Lowered by BMO Capital Markets $96.92 $147.00 → $142.00
2020-05-07 Outperform Target Lowered by Raymond James $96.92 $159.00 → $156.00
2020-05-07 Outperform Target Lowered by SVB Leerink $96.92 $156.00 → $150.00
2020-05-07 Equal Weight Target Raised by Morgan Stanley $96.92 $116.00 → $120.00
2020-05-06 Buy Reiterated by Nomura $96.84 $133.00
2020-05-06 Strong-Buy Target Lowered by Cfra $96.84 $165.00 → $159.00
2020-05-05 Outperform - Market Perform Downgraded by William Blair $98.25
2020-04-27 Neutral Initiated by Cantor Fitzgerald $110.86
2020-04-20 Reduce Reiterated by UBS Group $106.72
2020-04-17 Overweight Target Lowered by JPMorgan Chase & Co. $103.48 $168.00 → $163.00
2020-04-15 Equal Weight Target Lowered by Morgan Stanley $96.94 $127.00 → $116.00

ALXN Stock Trend

The stock is moving within a narrow and horizontal trend and further movements within this trend can be expected.

Given the current horizontal trend, you can expect Alexion Pharmaceuticals stock with a 90% probability to be traded between $178.11 and $185.20 at the end of this 3-month period. A break of a horizontal trend is often followed by a large increase in the volume, and stocks seldom manage to go directly from the bottom of a trend up to the top. Stocks turning up in the middle of a horizontal trend are therefore considered to be potential runners.

Data

Date Bottom Mid Top
2021-09-23 $178.86 $182.42 $185.99
2021-09-24 $178.85 $182.41 $185.97
2021-09-27 $178.84 $182.40 $185.96
2021-09-28 $178.83 $182.39 $185.95
2021-09-29 $178.81 $182.37 $185.93
2021-09-30 $178.80 $182.36 $185.92
2021-10-01 $178.79 $182.35 $185.91
2021-10-04 $178.77 $182.34 $185.90
2021-10-05 $178.76 $182.32 $185.88
2021-10-06 $178.75 $182.31 $185.87
2021-10-07 $178.74 $182.30 $185.86
2021-10-08 $178.72 $182.28 $185.85
2021-10-11 $178.71 $182.27 $185.83
2021-10-12 $178.70 $182.26 $185.82
2021-10-13 $178.69 $182.25 $185.81
2021-10-14 $178.67 $182.23 $185.79
2021-10-15 $178.66 $182.22 $185.78
2021-10-18 $178.65 $182.21 $185.77
2021-10-19 $178.63 $182.20 $185.76
2021-10-20 $178.62 $182.18 $185.74
2021-10-21 $178.61 $182.17 $185.73
2021-10-22 $178.60 $182.16 $185.72
2021-10-25 $178.58 $182.14 $185.71
2021-10-26 $178.57 $182.13 $185.69
2021-10-27 $178.56 $182.12 $185.68
2021-10-28 $178.55 $182.11 $185.67
2021-10-29 $178.53 $182.09 $185.65
2021-11-01 $178.52 $182.08 $185.64
2021-11-02 $178.51 $182.07 $185.63
2021-11-03 $178.49 $182.06 $185.62

About Alexion Pharmaceuticals

Alexion Pharmaceuticals Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; and atypical hemolytic uremic syndrome (aHUS), a genetic disease. It provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosp... Read more

Golden Star Signal

This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star.

This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!

Get access to Golden Star list now!

StockInvest.usJoin 95.000+ Happy Subscribers

Don't miss out on the runners!

Get The StockInvest.Us Newsletter

StockInvest.usStock Podcast

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT